Literature DB >> 33511572

COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics.

Lauren Caton1, Hannah Cheng1, Hélène Chokron Garneau1, Tammy Fisher2, Briana Harris-Mills2, Brian Hurley3,4, Sandra Newman2, Mark P McGovern5,6.   

Abstract

BACKGROUND: With the onset of the COVID-19 crisis, many federal agencies relaxed policies regulating opioid use disorder treatment. The impact of these changes has been minimally documented. The abrupt nature of these shifts provides a naturalistic opportunity to examine adaptations for opioid use disorder treatment in primary care.
OBJECTIVE: To examine change in medical and behavioral health appointment frequency, visit type, and management of patients with opioid use disorder in response to COVID-19.
DESIGN: A 14-item survey queried primary care practices that were enrolled in a medications for opioid use disorder statewide expansion project. Survey content focused on changes in service delivery because of COVID-19. The survey was open for 18 days. PARTICIPANTS: We surveyed 338 clinicians from 57 primary care clinics located in California, including federally qualified health centers and look-alikes. A representative from all 57 clinics (100%) and 118 staff (34.8% of all staff clinicians) participated in the survey. MAIN MEASURES: The survey consisted of seven dimensions of practice: medical visits, behavioral health visits, medication management, urine drug screenings, workflow, perceived patient demand, and staff experience. KEY
RESULTS: A total of 52 of 57 (91.2%) primary care clinics reported practice adaptations in response to COVID-19 regulatory changes. Many clinics indicated that both medical (40.4%) and behavioral health visits (53.8%) were now exclusively virtual. Two-thirds (65.4%) of clinics reported increased duration of buprenorphine prescriptions and reduced urine drug screenings (67.3%). The majority (56.1%) of clinics experienced an increase in patient demand for behavioral health services. Over half (56.2%) of clinics described having an easier or unchanged experience retaining patients in care.
CONCLUSIONS: Many adaptations in the primary care approach to patients with opioid use disorder may be temporary reactions to COVID-19. Further evaluation of the impact of these adaptations on patient outcomes is needed to determine whether changes should be maintained post-COVID-19.

Entities:  

Keywords:  COVID-19; medications for opioid use disorder (MOUD); office-based opioid treatment (OBOT); opioid use disorder (OUD); telehealth

Year:  2021        PMID: 33511572      PMCID: PMC7842998          DOI: 10.1007/s11606-020-06436-3

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  14 in total

1.  Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States.

Authors:  Corey S Davis; Derek H Carr
Journal:  Int J Drug Policy       Date:  2019-07-20

2.  Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.

Authors:  Kevin Fiscella; Sarah E Wakeman; Leo Beletsky
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

3.  Barriers to primary care physicians prescribing buprenorphine.

Authors:  Eliza Hutchinson; Mary Catlin; C Holly A Andrilla; Laura-Mae Baldwin; Roger A Rosenblatt
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

4.  Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment.

Authors:  Traci C Green; Jeffrey Bratberg; Deborah S Finnell
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

5.  Why aren't physicians prescribing more buprenorphine?

Authors:  Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2017-04-12

6.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

7.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

8.  Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.

Authors:  Arthur Robin Williams; Hillary Samples; Stephen Crystal; Mark Olfson
Journal:  Am J Psychiatry       Date:  2019-12-02       Impact factor: 18.112

9.  Advancing a conceptual model of evidence-based practice implementation in public service sectors.

Authors:  Gregory A Aarons; Michael Hurlburt; Sarah McCue Horwitz
Journal:  Adm Policy Ment Health       Date:  2011-01

10.  Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic.

Authors:  Adrian Dunlop; Buddhima Lokuge; Debbie Masters; Marcia Sequeira; Peter Saul; Grace Dunlop; John Ryan; Michelle Hall; Nadine Ezard; Paul Haber; Nicholas Lintzeris; Lisa Maher
Journal:  Harm Reduct J       Date:  2020-05-06
View more
  9 in total

Review 1.  The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.

Authors:  Colleen G Jordan; Amy L Kennalley; Alivia L Roberts; Kaitlyn M Nemes; Tenzing Dolma; Brian J Piper
Journal:  Pharmacy (Basel)       Date:  2022-04-19

2.  Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers.

Authors:  Minhee L Sung; Anne C Black; Derek Blevins; Brandy F Henry; Kathryn Cates-Wessel; Michael A Dawes; Karen Drexler; Holly Hagle; Todd Molfenter; Frances R Levin; William C Becker; E Jennifer Edelman
Journal:  J Addict Med       Date:  2022-01-11       Impact factor: 4.647

Review 3.  Converging public health crises: substance use during the coronavirus disease 2019 pandemic.

Authors:  Catherine W Striley; Carolin C Hoeflich
Journal:  Curr Opin Psychiatry       Date:  2021-07-01       Impact factor: 4.741

4.  Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.

Authors:  Ellis Jaewon Yeo; Hannah Kralles; David Sternberg; Dana McCullough; Ajetha Nadanasabesan; Richard Mayo; Hana Akselrod; Jillian Catalanotti
Journal:  Harm Reduct J       Date:  2021-12-09

Review 5.  Coronavirus Disease 2019 and the Impact on Substance Use Disorder Treatments.

Authors:  Osnat C Melamed; Wayne K deRuiter; Leslie Buckley; Peter Selby
Journal:  Psychiatr Clin North Am       Date:  2021-11-12

6.  Client perspectives on the accessibility and quality of substance use treatment during the COVID-19 pandemic.

Authors:  Randolph D Hubach; Andrew M O'Neil; Campbell Ernst; Mollie Stowe; Mark Hickey; Molly Remondino; Zachary Giano
Journal:  Drug Alcohol Depend Rep       Date:  2021-11-22

Review 7.  Illicit Substance Use and the COVID-19 Pandemic in the United States: A Scoping Review and Characterization of Research Evidence in Unprecedented Times.

Authors:  Anh Truc Vo; Thomas Patton; Amy Peacock; Sarah Larney; Annick Borquez
Journal:  Int J Environ Res Public Health       Date:  2022-07-21       Impact factor: 4.614

Review 8.  Telehealth-Based Delivery of Medication-Assisted Treatment for Opioid Use Disorder: a Critical Review of Recent Developments.

Authors:  Hossam Mahmoud; Hady Naal; Emile Whaibeh; Alyson Smith
Journal:  Curr Psychiatry Rep       Date:  2022-07-27       Impact factor: 8.081

9.  Changes in Buprenorphine Prescribing to Medicaid Beneficiaries During the First Year of the COVID-19 Pandemic.

Authors:  William N Dowd; Tami L Mark
Journal:  JAMA Netw Open       Date:  2022-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.